Active and passive data collection using mHealth to monitor mental wellness: Pilot findings from the Texas resilience against depression study - Report - MDSpire

Active and passive data collection using mHealth to monitor mental wellness: Pilot findings from the Texas resilience against depression study

  • By

  • Cherise R. Chin Fatt

  • Abu Minhajuddin

  • Srividya Vasu

  • Lynnel C. Goodman

  • Sangita Sethuram

  • Madhukar H. Trivedi

  • June 8, 2026

  • 0 min

Share

Clinical Report: Utilizing mHealth for Active and Passive Data Gathering

Overview

The Texas Resilience Against Depression Study explores the feasibility of a mobile health application designed to collect both active and passive data to assess mental health. Preliminary results indicate potential for continuous monitoring of behavioral patterns and mood-related symptoms.

Background

Major Depressive Disorder (MDD) is prevalent among American adults, with rates rising significantly from 20.6% in 2017 to 29% in 2023. The integration of digital phenotyping through mobile health applications offers a novel approach to continuously monitor mental health, addressing the limitations of traditional assessment methods that often miss dynamic symptom variations.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

  • The mHealth application collects both active and passive data, including GPS and accelerometer data.
  • Digital phenotyping can provide insights into behavioral patterns related to mood and functioning.
  • Smartphones are widely used, facilitating the collection of behavioral data relevant to mental health.
  • Passive data collection may help identify gaps in clinical practice regarding depression diagnosis and treatment.
  • Prior research indicates that digital tools can monitor fluctuations in mood and behavior over time.

Clinical Implications

The mHealth application may enhance the ability to monitor mental health continuously, potentially improving early diagnosis and treatment of depression. This approach could reduce the burden of depression in patients with comorbid medical conditions.

Conclusion

The pilot implementation of the mHealth application demonstrates feasibility for integrating continuous data collection in mental health research, which may lead to better understanding and management of depressive symptoms.

Related Resources & Content

  1. Frontiers in Psychiatry, 2026 -- Prospective observational study on behavioral monitoring, disease progression assessment, and screening model development for patients with depression using wearable devices and mobile phones: protocol
  2. Frontiers in Digital Health, 2026 -- Mental Health Outcomes and Use of Online Mental Health Tools Following a Public Health Deployment of the Mindfulness Meditation App Headspace
  3. Frontiers in Psychiatry, 2026 -- Feasibility of smartphone app-based neuropsychological tasks for screening people with subclinical depression and anxiety: a preliminary validation study
  4. Recommendation: Depression and Suicide Risk in Adults: Screening | United States Preventive Services Taskforce
  5. Overview | Depression in adults: treatment and management | Guidance | NICE
  6. Frontiers in Digital Health — Digital phenotyping of affect and stress in emerging adults
  7. Digital health
  8. Mental Health Apps
  9. Recommendation: Depression and Suicide Risk in Adults: Screening | United States Preventive Services Taskforce
  10. Overview | Depression in adults: treatment and management | Guidance | NICE
  11. Cognitive behavioral therapy skills via a smartphone app for subthreshold depression among adults in the community: the RESiLIENT randomized controlled trial | Nature Medicine
  12. Transdiagnostic-focused apps for depression and anxiety: a meta-analysis | npj Digital Medicine
  13. Current evidence on the efficacy of mental health smartphone apps for symptoms of depression and anxiety. A meta‐analysis of 176 randomized controlled trials - PMC
  14. U.S. Food and Drug Administration (FDA) Clearance of Rejoyn® First Prescription Digital Therapeutic Authorized in the U.S. for the Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms|April 2, 2024|News Releases | Otsuka Pharmaceutical Co., Ltd.
  15. https://www.nature.com/articles/s41746-026-02706-2_reference.pdf
  16. Journal of Medical Internet Research - Passive Sensing for Mental Health Monitoring Using Machine Learning With Wearables and Smartphones: Scoping Review
  17. Clinical and sociodemographic features of the Texas resilience against depression (T-RAD) study: Findings from the initial cohort - ScienceDirect

Original Source(s)

Related Content